Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia

• Published in: Blood advances Vol. 1; no. 5; pp. 319 - 329
• Main Authors: Reina-Castillón, Judith, Pujol, Roser, López-Sánchez, Marcos, Rodríguez-Santiago, Benjamín, Aza-Carmona, Miriam, González, Juan Ramón, Casado, José Antonio, Bueren, Juan Antonio, Sevilla, Julián, Badel, Isabel, Català, Albert, Beléndez, Cristina, Dasí, María Ángeles, Díaz de Heredia, Cristina, Soulier, Jean, Schindler, Detlev, Pérez-Jurado, Luis Alberto, Surrallés, Jordi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 24.01.2017; American Society of Hematology; Elsevier
• Subjects: Biochemical markers; Cancer; Càncer; Marcadors bioquímics; Myeloid Neoplasia
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2016000943

Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 × 10−9). Compared with 15 743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 × 10−16). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 × 10−5), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 × 10−5). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients. •Fanconi anemia patients have exacerbated cytogenetic clonal mosaicism as detected by molecular karyotyping of blood DNA with SNP assays.•Bone marrow clonal abnormalities can be detected in blood DNA and used as biomarkers of cancer risk and poor prognosis.